- Home
- CSGP vs EXEL Comparison
CSGP vs EXEL Comparison
Compare CSGP & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CSGP | EXEL |
|---|---|---|
| Founded | 1987 | 1994 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 13.4B | 14.0B |
| IPO Year | 1998 | 2000 |
Fundamental Metrics
Financial Performance| Metric | CSGP | EXEL |
|---|---|---|
| Price | $30.46 | $53.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 21 |
| Target Price | ★ $60.57 | $46.50 |
| AVG Volume (30 Days) | ★ 7.6M | 2.5M |
| Earning Date | 04-28-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.95 |
| EPS | 0.14 | ★ 1.60 |
| Revenue | ★ $965,230,000.00 | $452,477,000.00 |
| Revenue This Year | $19.71 | $13.61 |
| Revenue Next Year | $12.40 | $13.13 |
| P/E Ratio | $211.29 | ★ $32.63 |
| Revenue Growth | ★ 15.23 | N/A |
| 52 Week Low | $25.89 | $33.76 |
| 52 Week High | $94.93 | $57.57 |
Technical Indicators
Market Signals| Indicator | CSGP | EXEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 41.17 |
| Support Level | $28.18 | $50.80 |
| Resistance Level | $31.20 | $52.84 |
| Average True Range (ATR) | 1.44 | 1.82 |
| MACD | 0.24 | -0.35 |
| Stochastic Oscillator | 66.95 | 8.49 |
Price Performance
Historical ComparisonAbout CSGP CoStar Group Inc.
CoStar Group is a global provider of proprietary information, analytics, and online marketplaces serving both commercial and residential real estate. The firm operates through a diverse portfolio of brands, including CoStar Suite for commercial real estate research, LoopNet for commercial listings, Apartments.com for multifamily rentals, and Homes.com for residential brokerage. It primarily sells high-margin software-as-a-service subscriptions that provide institutional clients with forensic property data and premium advertising visibility. With operations across North America, Europe, and Asia-Pacific, CoStar maintains the industry's most comprehensive centralized real estate database, functioning as a critical information utility for brokers, lenders, and owners worldwide.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.